Liposomes to target the lymphatics by subcutaneous administration

Advanced Drug Delivery Reviews

Volumn 50, Issue 1-2, 2001, Pages 143-156

  Oussoren, Christien ^a   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Liposomes; Lymphatics; Subcutaneous; Targeting

Indexed keywords

ABSORPTION; AGENTS; COMPOSITION; DIAGNOSIS; LIPIDS;

LIPOSOMES; LYMPHATIC SYSTEMS;

DRUG DOSAGE;

ANTINEOPLASTIC AGENT; BIOTIN; DRUG CARRIER; LIGAND; LIPOSOME; MACROGOL; TECHNETIUM 99M;

CHEMICAL MODIFICATION; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; IMMUNOMODULATION; INJECTION SITE; LYMPH FLOW; LYMPH NODE; LYMPH NODE METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG CARRIERS; HUMANS; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; LYMPH NODES; LYMPHATIC SYSTEM;

EID: 0035940056     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00154-5     Document Type: Review

References (65)

1. Drug delivery to the lymphatic system
2. The pathogenesis of cancer metastasis
3. HIV infection is active and progressive in lympoid tissue during the clinically latent stage of disease
4. Massive covert infection of T-lymphocytes and macrophages by HIV during the clinically latent stage of disease
5. Lympoid tissue targeting of liposome-encapsulated 2′,3′-dideoxyinosine
6. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate
7. Potential for lymphatic targeting of peptides
8. An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems
9. Potential application of liposomes to therapy
10. Intramuscular absorption and regional lymphatic uptake of liposome-entrapped inulin
11. 14C adriamycin following intraperitoneal administration to rats
12. Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat
13. Lymphatic transport of liposome-encapsulated agents: Effects of liposome size following intraperitoneal administration
14. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose
15. Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection
16. Fate of liposomes in the lymphatics
17. Fate of cholesterol-rich liposomes after subcutaneous injection into rats
18. Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics
19. Fate and behaviour of liposomes in vivo: A review of controlling factors
20. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes
21. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes
22. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. III. Influence of surface modification with poly(ethyleneglycol)
23. Lymph node localization of non-specific anti-body coated liposomes
24. Modified in vivo behaviour of liposomes containing synthetic glycolipids
25. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab′ fragments
26. Novel method of greatly enhanced delivery of liposomes to lymph nodes
27. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. I. Influence of the anatomical site of injection
28. The kinetics of macromolecule transport in lymph and colloid accumulation in lymph nodes
29. Anatomy and physiology of the lymphatics
30. Are the initial lymphatics normally pulled open by the anchoring filaments?
31. Magnetic resonance lymphography of profunded lymph nodes with liposomal gadolinium-diethylenetriamine penta-acetic acid
32. Massage-induced release of subcutaneously injected liposome-encapsulated drugs to the blood
33. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. IV. Fate of liposomes in regional lymph nodes
34. Morphological observations on the fate of liposomes in the regional lymph nodes after footpad injection into rats
35. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
36. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
37. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study
38. Repopulation of macrophages in popliteal lymph nodes of mice after liposome-mediated depletion
39. Radionuclide-labelled liposomes - A new lymph node imaging agent
40. Potential applications of radionuclide-labelled liposomes in the detection of lymphatic spread of cancer
41. The preoperative detection of axillary lymph node metastates in breast cancer by isotope imaging
42. Distribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously
43. PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide
44. The effect of lymphatic oedema on the uptake of colloids to the lymph nodes
45. Surface-modified liposomes in gamma- and MR-imaging
46. Interstitial MR lymphography using GD-carrying liposomes
47. Targeted delivery of diagnostic agents by surface-modified liposomes
48. Controlled delivery of Gd-containing liposomes to lymph nodes: Surface modification may enhance MRI contrast properties
49. Effect of route of administration and liposome entrapment on the metabolism and disposition of adriamycin in the rat
50. Carrier activity of sonicated small liposomes containing melphalan to regional lymph nodes of rats
51. Absorption characteristics of the lipophilic prodrug of mitomycin C from injected liposomes or an emulsion
52. 3H]methotrexate-encapsulated neutral large unilamellar vesicles and immunoliposomes
53. Chemotherapy targeting regional lymph nodes by gastric submucosal injection of liposomal adriamycin in patients with gastric carcinoma
54. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats
55. Intralymphatic administration of liposome-encapsulated drugs to mice: Possibility for suppression of the growth of tumor metastases in the lymph nodes
56. Enhanced lymph node uptake of melphalan following liposomal entrapment and effects on lymph node metastasis in rats
57. The antitumor effects of adriamycin entrapped in liposomes on lymph node metastases
58. Effect of sulfatide-inserted liposomes containing entrapped adriamycin on metastasised cells in lymph nodes
59. Experimental model of doxorubicin extravasation in the mouse
60. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs
61. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities and antitumor efficacy of doxorubicin
62. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes
63. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages
64. Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells
65. Lymphatic drug targeting with liposomal mitoxantrone for breast cancer - Results of a pilot study